According to a report released by LiveMint, approval for a late-stage clinical trial of the protein-based coronavirus vaccine candidate has been received by Sanofi SA and GlaxoSmithKlein Plc from the Indian authorities.
To include more than 35,000 adults to test the dose, France’s Sanofi along with Britain’s GSK kicked off global trials in May. After early-stage results showcased the vaccine producing a robust immune response, they hope to get approvals by the end of 2021, as added in the report.
As per India’s clinical trial registry, vaguely 3,000 adults between the ages of 18 years and 55 shall be enrolled by the Indian arm of the studies. As the first enrollment in India is shown to have been made on Tuesday, the assessment is expected to run for around a year.
According to data from the health ministry, around 46,000 new COVID-19 cases have been reported by India on Thursday in the last 24 hours. As the death toll surpassed the four million mark worldwide, the global recovery plans are been hurt by the highly contagious Delta variant of the coronavirus which was first identified in the South Asian country.
The technology which was used in one of Sanofi’s seasonal influenza vaccines is also being used by GSK and Sanofi’s vaccine candidate. Acting as a booster to the shot it shall be coupled with the adjuvant substance which is made by GSK.
